Definium Therapeutics
About Definium Therapeutics
Definium Therapeutics is a biopharmaceutical company focused on developing psychedelic medicine to advance psychiatry and brain health. The company is pursuing therapies for anxiety, depression, and autism spectrum disorder by leveraging psychedelic compounds and neuroscience research, with a pipeline that includes DT120 and DT402. Headquartered in New York, Definium aims to deliver science-led, evidence-backed treatments and to redefine mental healthcare with transparent and responsible practices.
Recent News
Can an LSD Candidate Do for Anxiety What Spravato Did for Depression?
StockWatch: Trump Order Lifts Psychedelic Drug Shares
New Antidepressants: Tackling Treatment Resistant Depression
Psychedelic Stocks Jump as High as 40% After Trump Supports Using Drugs Like LSD for Mental Health
Psychedelic-Assisted Therapies Get a Boost, but Systems Struggle to Play Catch-Up
Psychedelics Space at a ‘Tipping Point’ as Compass, Definium Gear Up To File for Approval
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
Trump's Executive Order Fast‑Tracks Psychedelic Therapy Review, Boosting Compass Pathways
Pasithea Therapeutics Corp (KTTA) Q1 2026 Earnings Call Transcript
Recent Deals
No recent deals for this company.